Translational gastroenterology and hepatology最新文献

{"title":"The appendix and ulcerative colitis: from an unsolved connection to a therapeutic strategy.","authors":"Antonio Caballero-Mateos, Beatriz Gros, Eduard Brunet-Mas","doi":"10.21037/tgh-2026-0101","DOIUrl":"https://doi.org/10.21037/tgh-2026-0101","url":null,"abstract":"","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"11 ","pages":"122"},"PeriodicalIF":2.5,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149187543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconsidering therapeutic strategies after biologic failure in ulcerative colitis: appendectomy versus Janus kinase inhibition.","authors":"Annika Gauss, Peter Kienle","doi":"10.21037/tgh-2026-0130","DOIUrl":"https://doi.org/10.21037/tgh-2026-0130","url":null,"abstract":"","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"11 ","pages":"117"},"PeriodicalIF":2.5,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149187422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The overlooked surface: cutaneous manifestations of inflammatory bowel disease.","authors":"Kadhim Al-Rubaye, Laith Alrubaiy","doi":"10.21037/tgh-2025-142","DOIUrl":"https://doi.org/10.21037/tgh-2025-142","url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD) is characterized by a chronic, idiopathic inflammation of the intestinal tract. The primary types include ulcerative colitis (UC), which affects the colon and rectum with continuous mucosal and submucosal lesions solely and Crohn's disease (CD), which may involve any segment of the gastrointestinal tract with discontinuous lesions. Among extraintestinal manifestations (EIMs), the skin is most frequently involved. Erythema nodosum (EN) and pyoderma gangrenosum (PG) are identified as the most prevalent cutaneous presentations. This review explores the underlying mechanisms, clinical features, and treatment options for skin symptoms in IBD, including Sweet's syndrome (SS), metastatic CD (MCD), psoriasis, hidradenitis suppurativa (HS), EN, and PG. Studies show that having one EIM increases the chance of developing others. Biologic drugs have revolutionized IBD treatment but can cause various skin side effects. Although the precise mechanisms linking IBD to these dermatological conditions remain incompletely understood, shared immune pathways and genetic predispositions suggest an association. Factors like genetics, immune system disturbances, changes in gut and skin microbiota, environmental factors, treatments, and epigenetics all play roles. These factors interact through the gut-skin immune link, causing systemic inflammation that can trigger skin issues. Further research is imperative to elucidate the fundamental mechanisms underlying these cutaneous presentations.</p>","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"11 ","pages":"113"},"PeriodicalIF":2.5,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149187562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital cognitive behavioural self-management programme for fatigue, pain, urgency and incontinence in inflammatory bowel disease.","authors":"Samuel Majna, Mohmmed Tauseef Sharip, Nurulamin M Noor","doi":"10.21037/tgh-2026-0088","DOIUrl":"https://doi.org/10.21037/tgh-2026-0088","url":null,"abstract":"","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"11 ","pages":"124"},"PeriodicalIF":2.5,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149187388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tobevibart plus elebsiran in hepatitis D: crossing a therapeutic threshold.","authors":"Javier Crespo, Joaquín Cabezas","doi":"10.21037/tgh-2026-0099","DOIUrl":"https://doi.org/10.21037/tgh-2026-0099","url":null,"abstract":"","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"11 ","pages":"118"},"PeriodicalIF":2.5,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149186740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and laboratory characteristics associated with ascites in patients with MASLD-related cirrhosis: a cross-sectional study.","authors":"Emad S Aljahdli, Hind Fallatah, Nouf Adil Turki","doi":"10.21037/tgh-2026-0089","DOIUrl":"https://doi.org/10.21037/tgh-2026-0089","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition globally. It is underexplored in Saudi Arabia, particularly its clinical and biochemical factors associated with hepatic decompensation (ascites) among MASLD-related cirrhosis. The objective is to describe and compare the demographic, clinical, biochemical, and laboratory profile of MASLD-related cirrhosis in the presence or absence of ascites. The importance of routine monitoring correlated with hepatic decompensation was also explored.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This cross-sectional study was conducted, in which data were collected from hepatology electronic medical records at King Abdulaziz University Hospital for patients managed between January and July 2025. Eligible adults (≥18 years) had MASLD-related cirrhosis, defined by hepatic steatosis on imaging with at least one cardiometabolic risk factor and exclusion of other liver disease aetiologies, with cirrhosis confirmed by ultrasound, computed tomography (CT), transient elastography, or biopsy. Patients were classified by presence or absence of ascites, diagnosed clinically and/or by ultrasound. Demographic, anthropometric, haematological, and biochemical variables, together with the fibrosis-4 (FIB-4) index and non-alcoholic fatty liver disease (NAFLD) Fibrosis Score (NFS), were compared between groups using independent-samples t-tests (with Welch correction where indicated) and chi-square/Fisher's exact tests. Binary logistic regression was used to explore associations between clinical/laboratory variables and the presence of ascites, using SPSS version 27.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;There were 41 MASLD cirrhosis patients (56.1% women, 68.3% Saudi): 14 (34.1%) with ascites and 27 (65.9%) without. Patients with ascites had significantly lower serum albumin (33.25±8.05 &lt;i&gt;vs.&lt;/i&gt; 39.50±6.35 g/L; P=0.01) than those without; platelet counts (102.25±46.69 &lt;i&gt;vs.&lt;/i&gt; 164.42±116.08 ×10&lt;sup&gt;9&lt;/sup&gt;/L) and aminotransferases were numerically lower in the ascites group but did not reach statistical significance in bivariate comparison than those without ascites. In exploratory binary logistic regression, higher body mass index (BMI) showed a trend toward association with ascites that did not reach statistical significance [odds ratio (OR) 1.175, 95% confidence interval (CI): 0.998-1.385, P=0.054]; lower white blood cell (WBC) count (OR 0.315, P=0.01), lower alanine aminotransferase (ALT) (OR 0.832, P=0.03), and lower albumin (OR 0.790, P=0.01) were independently associated with ascites, these estimates should be interpreted with caution, as confidence intervals were wide and the model may be unstable.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;In this cross-sectional sample of Saudi patients with MASLD-related cirrhosis, lower serum albumin, lower ALT, and lower white cell count were associated with the presence of ascites; higher BMI showed a similar trend that did not reac","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"11 ","pages":"96"},"PeriodicalIF":2.5,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149187379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision infliximab rescue in acute severe ulcerative colitis.","authors":"Anastasia K Bogdanovski, Daniel J Wong","doi":"10.21037/tgh-2026-0066","DOIUrl":"https://doi.org/10.21037/tgh-2026-0066","url":null,"abstract":"","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"11 ","pages":"125"},"PeriodicalIF":2.5,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149187402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Not whether, but for whom: EUS-guided choledochoduodenostomy and the prevention of post-procedural pancreatitis in malignant distal biliary obstruction.","authors":"Ishaan Vohra","doi":"10.21037/tgh-2026-0129","DOIUrl":"https://doi.org/10.21037/tgh-2026-0129","url":null,"abstract":"","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"11 ","pages":"116"},"PeriodicalIF":2.5,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149187496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tobevibart plus elebsiran for the treatment of hepatitis D: how should we read the phase 2 data?","authors":"Tatyana Kushner, Nancy Reau","doi":"10.21037/tgh-2026-0094","DOIUrl":"https://doi.org/10.21037/tgh-2026-0094","url":null,"abstract":"","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"11 ","pages":"123"},"PeriodicalIF":2.5,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149186776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What did the prospective validation of the Pancreatic Fistula Risk Classification by the International Study Group for Pancreatic Surgery (PARIS) trial tell us?","authors":"Alfred Wei Chieh Kow","doi":"10.21037/tgh-2026-0102","DOIUrl":"https://doi.org/10.21037/tgh-2026-0102","url":null,"abstract":"","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"11 ","pages":"119"},"PeriodicalIF":2.5,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149186898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}